In biomarker discovery studies, uncertainty associated with case and control labels is often overlooked. By omitting to take into account label uncertainty, model parameters and the predictive risk can become biased, sometimes severely. The most common situation is when the control set contains an unknown number of undiagnosed, or future, cases. This has a marked impact in situations where the model needs to be well-calibrated, e.g., when the prediction performance of a biomarker panel is eva...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Accounting for control mislabeling in case-control biomarker studies.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record